Biophan Announces Online Availability of ValueRich Magazine Article on Company's Advanced Biomedical Technology.

ROCHESTER, N.Y. -- Article Features Proprietary Biophan Nanotechnology Solutions to Make Medical Devices Safe and Compatible with MRI Systems

Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, announced today the online availability of an in-depth feature story illustrated with high-quality explanatory graphics about the Company's advanced biotechnology innovations, which was recently published in the Summer 2005 issue of ValueRich Magazine.

The article discusses Biophan's comprehensive solutions to make medical devices and surgical tools safe and image-compatible with Magnetic Resonance Imaging (MRI) systems, and provides insight into the global marketplace potential for such solutions. "Over $12 billion worth of medical devices shipped annually are not safe for use with MRI and/or are not imageable," the article states. "Due to safety concerns including heating of devices and metal wire leads which can cause tissue damage, most MRI imaging centers currently refuse patients with pacemakers and other implanted medical devices, meaning they are denied access to one of the most important diagnostic tools in medicine. Rather than accepting this as an unavoidable limitation of the technology, Biophan set out to solve the problem."

Biophan recently signed a landmark agreement to license some of its proprietary technologies to leading medical device manufacturer, Boston Scientific (NYSE: BSX). Biophan also is in discussions with other major manufacturers.

To view the ValueRich article, please visit http://www.biophan.com/articles/0705_ValueRich5.pdf

About ValueRich Magazine

ValueRich Magazine is a finance and luxury lifestyle magazine with a circulation of fifty eight thousand readers. It is sent directly to the chief executives of publicly traded companies in the United States as well as investment bankers, venture capitalists, and qualified private investors in both the United States and Europe. It reaches a very specific and affluent group of readers who travel regularly and are not easily reached through other means. Additionally, ValueRich hosts conventions each year in New York and Palm Beach, Florida. Please visit www.valuerichonline.com for more information.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents. Biophan is developing other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 142 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 95 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.